Industry Buzz: The 10 Biggest DX Mergers of 2019
Conspicuous by its absence from the list is the proposed $1.2 billion Illumina takeover of Pacific Biosciences which suddenly seems to be in major trouble. Here are the 10-highest value M&A diagnostics deals that did come off in 2019.
Conspicuous by its absence from the list is the proposed $1.2 billion Illumina takeover of Pacific Biosciences which suddenly seems to be in major trouble. Here are the 10-highest value M&A diagnostics deals that did come off in 2019.
Top 10 Lab M&A Deals of 2019
| Rank | Buyer | Target | Reported Price |
| 1 | Danaher | GE Biopharma | $21.4 billion |
| 2 | Exact Sciences | Genomic Health | $2.8 billion (cash + stock) |
| 3 | Thermo Fisher Scientific | Brammer Bio | $1.7 billion |
| 4 | Agilent Technologies | BioTek Instruments | $1.17 billion |
| 5 | PHC Holdings (formerly known as Panasonic Healthcare Holdings) | Thermo Fisher Scientific | $1.14 billion |
| 6 | Sartorius | Danaher | $750 million* |
| 7 | Covance Drug Development (part of LabCorp) | Envigo | $485 million |
| 8 | Beckman Coulter Life Sciences | Labcyte | $308 million |
| 9 | PerkinElmer | Cisbio Bioassays | $219.8 million |
| 10 | Clayton, Dubilier & Rice investment funds | Cynosure (owned by Hologic) | $205 million |
* Announced in 2019 with closing scheduled for 2020
Subscribe to view Essential
Start a Free Trial for immediate access to this article